Novo Nordisk Option Alert: Jan 16 $110 Calls at the Bid: 1200 vs 1937 OI

Novo Nordisk Option Alert: Jan 16 $110 Calls at the Bid: 1200 @ $5.05 vs 1937 OI; Ref=$82.955

Novo Nordisk Option Alert: May 16 $80 Calls Sweep (53) near the Ask: 1000 vs 378 OI

Novo Nordisk Option Alert: May 16 $80 Calls Sweep (53) near the Ask: 1000 @ $7.312 vs 378 OI; Ref=$81.87

Novo Nordisk Option Alert: Apr 17 $50 Calls at the Bid: 200 vs 2 OI

Novo Nordisk Option Alert: Apr 17 $50 Calls at the Bid: 200 @ $32.36 vs 2 OI; Ref=$81.77

Novo Nordisk (NYSE:NVO) 주식

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Eli Lilly and Co.

Analyst Color

Biotech

Large Cap

News

Health Care

Initiation

Analyst Ratings

General

캔터 피츠제럴드는 월요일(21일) 일라이 릴리(NYSE:LLY)에 대한 커버리지를 개시하면서 비만치료제 시장 지배력을 강화할 오포글리프론(orforglipron) 데이터를 인용했다.

일라이 릴리, 경구용 비만치료제로 시장 지배력 강화 준비···애널리스트 반응 긍정적

Business,Finance,And,Investment,,Analyze,Economic,Growth,Charts,For,Informed

Equities

Markets

NFLX

TSLA

목요일(17일) 미국 증시는 무역 협상에 대한 낙관론이 커지면서 위험 선호도가 다시 살아났다. 도널드 트럼프 대통령은 유럽연합 및 중국과의 합의에 대한 자신감을 표했다. 넷플릭스, 유나이티드헬스, 노보 노디스크, 테슬라 및 트럼프 미디어

목요일 주목받은 주식: 넷플릭스, 유나이티드헬스, 노보 노디스크, 테슬라 및 트럼프 미디어

Eli Lilly

Trading Ideas

AMGN

일라이 릴리(NYSE:LLY) 주가는 목요일(17일)에 25년 만에 최대 일일 랠리를 기록했다. 이는 체중감량 약물 시장에서의 리더십을 확립할 수 있는 주요 임상 시험 데이터를 공개했기 때문이다. 체중감량 시장은 2030년까지 3배 이상 성장할 것으로 예상된다.

일라이 릴리, 경구용 체중감량 신약 임상 성공으로 주가 14% 폭등···애널리스트 반응은?

Novo Nordisk AS

Precidian ETFs Trust Novo Nordisk A/S B Shares ADRhedged

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$22.00</td>
<td>$44.8K</td>
<td>10.4K</td>
<td>9.6K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$80.00</td>
<td>$29.2K</td>
<td>424</td>
<td>839</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$60.00</td>
<td>$30.9K</td>
<td>8.4K</td>
<td>636</td>
</tr>
<tr>
<td>SMMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$25.00</td>
<td>$34.2K</td>
<td>60</td>
<td>361</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$72.50</td>
<td>$116.2K</td>
<td>52</td>
<td>350</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$66.00</td>
<td>$46.1K</td>
<td>367</td>
<td>320</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$157.50</td>
<td>$60.1K</td>
<td>4</td>
<td>294</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$880.00</td>
<td>$43.9K</td>
<td>2.3K</td>
<td>106</td>
</tr>
<tr>
<td>GEHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$62.00</td>
<td>$27.6K</td>
<td>5</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a put option sweep that happens to be bearish, expiring in 4 day(s) on May 2, 2025. This event was a transfer of 2800 contract(s) at a $22.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $44.8K, with a price of $16.0 per contract. There were 10427 open contracts at this strike prior to today, and today 9611 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 627 day(s) on January 15, 2027. This event was a transfer of 20 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $29.2K, with a price of $1460.0 per contract. There were 424 open contracts at this strike prior to today, and today 839 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bearish sentiment. It expires in 53 day(s) on June 20, 2025. Parties traded 183 contract(s) at a $60.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $30.9K, with a price of $169.0 per contract. There were 8483 open contracts at this strike prior to today, and today 636 contract(s) were bought and sold. 
• For SMMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), we notice a call option trade that happens to be bearish, expiring in 109 day(s) on August 15, 2025. This event was a transfer of 59 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $34.2K, with a price of $580.0 per contract. There were 60 open contracts at this strike prior to today, and today 361 contract(s) were bought and sold. 
• Regarding EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we observe a put option trade with bullish sentiment. It expires in 109 day(s) on August 15, 2025. Parties traded 350 contract(s) at a $72.50 strike. The total cost received by the writing party (or parties) was $116.2K, with a price of $332.0 per contract. There were 52 open contracts at this strike prior to today, and today 350 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bullish sentiment. It expires in 18 day(s) on May 16, 2025. Parties traded 278 contract(s) at a $66.00 strike. This particular call needed to be split into 29 different trades to become filled. The total cost received by the writing party (or parties) was $46.1K, with a price of $166.0 per contract. There were 367 open contracts at this strike prior to today, and today 320 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option sweep with bearish sentiment. It expires in 4 day(s) on May 2, 2025. Parties traded 204 contract(s) at a $157.50 strike. This particular put needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $60.1K, with a price of $295.0 per contract. There were 4 open contracts at this strike prior to today, and today 294 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bearish, expiring in 53 day(s) on June 20, 2025. This event was a transfer of 10 contract(s) at a $880.00 strike. The total cost received by the writing party (or parties) was $43.9K, with a price of $4395.0 per contract. There were 2310 open contracts at this strike prior to today, and today 106 contract(s) were bought and sold. 
• Regarding GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we observe a put option sweep with bullish sentiment. It expires in 18 day(s) on May 16, 2025. Parties traded 240 contract(s) at a $62.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $115.0 per contract. There were 5 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

GEHC

SMMT

9 Health Care Stocks Whale Activity In Today's Session

A federal court in Texas ruled in favor of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and the U.S. Food and Drug Administration (FDA), rejecting an attempt by a compounding pharmacy trade group to halt the FDA&#8217;s decision declaring that there is no longer a shortage of <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">semaglutide injectable drugs</a>.
In February, the compounding groups filed a lawsuit challenging the FDA&#8217;s decision to remove semaglutide from <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43986471/novo-nordisks-ozempic-and-wegovy-no-longer-on-fda-shortage-list-faces-lawsuit-over-decision" rel="noreferrer noopener">the drug shortage list</a>.
The plaintiffs argue that this action was arbitrary, unlawful, and detrimental to patients who rely on compounded semaglutide for type 2 diabetes, obesity, and cardiovascular disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44826319/novo-nordisk-flags-counterfeit-ozempic-circulating-in-us-market-with-fake-labels-and-needles" rel="noreferrer noopener">Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts</a>
The ruling reinforces the FDA&#8217;s position that Novo Nordisk&#8217;s Ozempic and Wegovy supplies meet or exceed national demand.
Following the court&#8217;s decision, the FDA is now authorized to take enforcement action against 503A pharmacies that continue to compound unauthorized versions of semaglutide drugs.
Additionally, the ruling <a target="_blank" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize" rel="noreferrer noopener">sets</a> May 22, 2025, as the deadline for 503B outsourcing facilities to stop producing compounded semaglutide injectables.
&#8220;We are pleased the court has rejected the compounders&#8217; attempts to undermine FDA&#8217;s data-based decision that the shortage of Wegovy and Ozempic is resolved,&#8221; <a target="_blank" href="https://www.prnewswire.com/news-releases/novo-nordisk-protects-us-patients-with-legal-wins-against-compounders-including-ruling-that-permanently-prohibits-compounding-pharmacy-from-selling-illegitimate-knockoff-wegovy-or-ozempic-302438372.html" rel="noreferrer noopener">said</a> Steve Benz, Corporate Vice President, Legal and US General Counsel, Novo Nordisk.
&#8220;With the end of the shortage of Wegovy and Ozempic, no patient should have to be exposed to unsafe, inauthentic &#8216;semaglutide&#8217; drugs,&#8221; Benz added.
The ruling also addresses growing concerns about compounded semaglutide products made using synthetic active pharmaceutical ingredients (APIs) imported overseas.
A Brookings Institute report warned that some Chinese manufacturers supplying these APIs operate without FDA inspection or compliance with good manufacturing practices.
The report identified six Chinese firms responsible for 65% of the semaglutide imported into the U.S. between March 2023 and September 2024—three of which have never been inspected and three others cited for violations.
Novo Nordisk has been aggressively pursuing legal action nationwide, filing 111 federal lawsuits in 32 states against entities selling unauthorized semaglutide.
Some compounded products contained high impurity levels—up to 33%—or lacked semaglutide altogether.
Courts have issued injunctions against numerous pharmacies and marketers, with some judgments exceeding $8 million.
The <a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4413417-1&amp;h=4272668996&amp;u=https%3A%2F%2Fwww.ic3.gov%2FPSA%2F2025%2FPSA250228&amp;a=Federal+Bureau+of+Investigation" rel="noreferrer noopener">Federal Bureau of Investigation</a> also recently warned the public about safety concerns related to fraudulent compounding practices associated with weight loss drugs, warning that &#8220;[s]ome healthcare providers are using compounded mixtures of unknown drugs that do not contain semaglutide, drugs with high levels of impurities, and unsafe or unapproved drugs.&#8221;
Price Action: NVO stock is down 1.23% at $61.86 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence" target="_blank" rel="noreferrer noopener">Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence</a></li>
</ul>
Image: Shutterstock

Legal

Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy

<ul>
<li>Federal court ruling leaves in place FDA's decision resolving the shortage of&nbsp;Wegovy&#xAE; and Ozempic&#xAE;, which are fully available nationwide, and ends the grace period for pharmacies to make or sell compounded "versions" of these medicines</li>
<li>Separate federal court ruling permanently bars&nbsp;MediOak Pharmacy LLC from marketing or selling illegitimate "semaglutide" drugs</li>
<li>Legal wins build on 111 lawsuits filed by Novo&nbsp;Nordisk across 32 states against entities unlawfully marketing and selling compounded "semaglutide" drugs, helping safeguard Americans from knockoffs made with unsafe or illicit foreign API</li>
<li>Novo&nbsp;Nordisk is dedicated to dialogue with companies to support patient access to authentic, FDA-approved Wegovy&#xAE; under the care of a licensed healthcare professional</li>
</ul>

Novo Nordisk: Federal Court Ruling Supports FDA, Ensures Nationwide Availability of Wegovy and Ozempic

As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Lexicon Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>)</h3>
<ul>
<li>On March 28, Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture, and commercialize LX9851 in all indications. The company's stock jumped around 95% over the past month and has a 52-week high of $2.45.</li>
<li>RSI Value: 73.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LXRX Price Action: Shares of Lexicon Pharmaceuticals gained 4.7% to close at $0.70 on Thursday.</li>
<li>Edge Stock Ratings: 5.71 Momentum score with Value at 55.06. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/lxrx"><img loading="lazy" decoding="async" width="472" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168.png" alt="" class="wp-image-888292" style="width:303px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168.png 472w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168-300x116.png 300w" sizes="(max-width: 472px) 100vw, 472px" /></a></figure>
<h3 class="wp-block-heading">Amarin Corporation PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>)</h3>
<ul>
<li>On March 12, Amarin announced its intent to effect a 1-for-20 ADS ratio change. The company also reported fourth-quarter financial results. &#8220;Since taking on the role of CEO of Amarin last year, I have worked with our leadership team and the Board of Directors to identify opportunities to leverage our unique assets, skills and resources to drive value,&#8221; said Aaron Berg, President &amp; CEO, Amarin. &#8220;In 2024, while still progressing with the early launch in markets outside the U.S. and despite a dynamic generic market in the U.S., we generated more than $200 million in revenue and ended the year with nearly $300 million in cash and no debt &#8212; all measures exemplifying the strength and resilience of our franchise and the impact of our disciplined approach to capital deployment.&#8221; The company's stock gained around 24% over the past five days and<a href="https://www.benzinga.com/quote/AMRN"> has a 52-week high</a> of $20.60.</li>
<li>RSI Value: 73.5</li>
<li>AMRN Price Action: Shares of Amarin rose 7.9% to close at $11.18 on Thursday.</li>
</ul>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44977071/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 7% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

AMRN

LXRX

Top 2 Health Care Stocks That May Crash This Month

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
What Happened:&nbsp;The Trump Administration is&nbsp;contemplating a policy to align U.S. drug prices with lower rates in other developed countries. The policy is likely to be enforced by the agency responsible for&nbsp;Medicare and Medicaid health programs, reported Reuters&nbsp;citing sources from the pharmaceutical industry.
The sources highlighted this policy as the pharmaceutical industry&#8217;s primary concern, surpassing other government actions under consideration, such as tariffs on imported medicines. One source labeled it as the most significant &#8220;existential&nbsp;threat to the industry and&nbsp;U.S. biosciences innovation.&#8221;
Though the Trump Administration hasn't directly addressed reference pricing, the conservative America First Policy Institute suggested it could be included in Medicare's drug price negotiations.
The industry trade group, PhRMA, has already approached Congress earlier this year regarding this issue, known as international reference pricing. The first source expressed apprehension about the potential upheaval this policy could trigger in the healthcare market, beyond just pharmaceuticals.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/44935195/elizabeth-warren-says-if-trump-illegally-fires-fed-chair-powell-hell-crash-our-markets-cause-more-economic-p" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says, &#8216;If Trump Illegally Fires Fed Chair Powell, He&#8217;ll Crash Our Markets, Cause More Economic Pain To American Families&#8217;</a>
Why It Matters: Under Biden&#8217;s Inflation Reduction Act, the U.S. began negotiating prices for its costliest drugs. However, the negotiated prices for the first 10 drugs remain over twice as high—and sometimes five times higher—than what drugmakers charge in other wealthy nations. During his first term, President Donald Trump&#8216;s attempt to implement an international reference pricing program was halted by a court ruling.
The current report by Reuters comes on the heels of President Trump&#8217;s executive order <a href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">aimed </a>at lowering drug prices and reducing Medicare costs signed earlier this month. The order instructed the Secretary of Health and Human Services to seek guidance for the Medicare Drug Price Negotiation Program for the initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028. 
This potential move is perceived as a major threat to the pharmaceutical industry. Boston University's Rena Conti told Reuters that drugmakers might respond to international reference pricing by raising prices in reference countries, potentially justifying higher U.S. prices and increasing global revenue.
Invesco Pharmaceuticals ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>) and iShares U.S. Pharmaceuticals ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) declined 8.6% and 7.5%, respectively over the past month.
Price Action: During the pre-market session on Wednesday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) gained 2.39%, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) climbed 1.16% and 1.07%, respectively. Meanwhile, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) edged 0.48% higher.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44930938/dogecoin-jumps-7-shiba-inu-up-4-is-a-major-meme-rally-brewing" target="_blank" rel="noreferrer noopener">Dogecoin Jumps 7%, Shiba Inu Up 4%: Is A Major Meme Rally Brewing? &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

iShares Dow Jones US Pharmaceuticals Index Fund

Trump Administration Considers Lowering US Drug Prices To International Levels: Report

Cantor Fitzgerald initiated coverage on Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Monday, citing orforglipron data, which strengthens <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">the case for obesity dominance</a>.
Last week, the U.S. drug giant reported topline Phase 3 results from the ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">diet and exercise alone</a>.
In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">using the efficacy estimand</a>.
After a choppy second half of 2024, &#8220;Lilly is off to a solid start in &#8217;25,&#8221; Cantor analyst Carter Gould writes. The company reported positive orforglipron ACHIEVE-1 data and improved underlying GLP-1 commercial metrics. 
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44907170/upcoming-pfizer-earnings-call-might-be-focused-on-tariffs-policy-risks-and-obesity-pipeline" rel="noreferrer noopener">Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline</a>
&#8220;&#8230;We view the ACHIEVE-1 data as meaningfully de-risking a 13-16% weight loss profile, and if safety/tolerability holds up, it should leave LLY well-positioned to take share from semaglutide and further grow the market with an oral approach,&#8221; analyst Gould adds.
Cantor writes that Eli Lilly could have an over 85% share of the obesity market by 2029-2030E when the next wave of entrants hits. Cantor initiated with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/LLY/analyst-ratings" rel="noreferrer noopener">price target of $975</a>.
Eli Lilly&#8217;s first-quarter earnings are in the front row for investors.
The company is scheduled to release the financial performance on 1 May. Analysts expect $4.79 per share earnings with <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $12.93 billion</a>.
Cantor expects modest beats across Mounjaro/Zepbound and that the company will likely reaffirm the FY25 topline guide ($59-61 billion) as a raise is more likely after the second quarter of 2025.
In March, the company announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest population of overweight or&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">obese people by 2050</a>.
Rival&nbsp;Novo Nordisk A/S&#8217;&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is feeling the pressure as it tries to move up the launch of Wegovy in India to better compete with Lilly.
BofA Securities has also made minor changes to its model for Eli Lilly ahead of Q1 earnings.
BofA analyst Tim Anderson writes that IQVIA recently began including Lilly Direct vials in its TRx (total prescription) data. As for pricing, Eli Lilly expects an overall price decline by the mid-to-high single digits in 2025. While this isn&#8217;t specific to any product, the company suggests that falling prices for its obesity drugs will likely be a major factor.
For 2025/2026, revenues are changed by +1%/+0.4%, and EPS estimates change by +1.9%/-0.7%. No substantial changes to Mounjaro/Zepbound forecasts.
BofA reiterates the Buy rating with a price target of $1,000. &#8220;We continue to like LLY, not &#8220;expensive&#8221; on a PE-to-growth basis, by our math.&#8221;
Price Action: LLY stock is up 0.59% at $822.84 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/04/44928828/devon-energy-unveils-1-billion-annual-optimization-plan-targets-efficiency-gains-by-2026" target="_blank" rel="noreferrer noopener">Devon Energy Unveils $1 Billion Annual Optimization Plan, Targets Efficiency Gains By 2026</a></li>
</ul>
Image: Shutterstock

Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) revealed 15 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $438,251, and 10 were calls, valued at $746,764.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Novo Nordisk during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $35.0 to $100.0 over the preceding 30 days.
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745344931_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$21.15</td>
<td>$20.15</td>
<td>$21.15</td>
<td>$80.00</td>
<td>$296.0K</td>
<td>3.8K</td>
<td align="right">10</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$30.75</td>
<td>$27.1</td>
<td>$29.0</td>
<td>$35.00</td>
<td>$145.0K</td>
<td>135</td>
<td align="right">0</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.7</td>
<td>$27.4</td>
<td>$27.4</td>
<td>$35.00</td>
<td>$137.0K</td>
<td>45</td>
<td align="right">50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$7.85</td>
<td>$7.75</td>
<td>$7.8</td>
<td>$55.00</td>
<td>$114.6K</td>
<td>330</td>
<td align="right">155</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$7.9</td>
<td>$7.7</td>
<td>$7.8</td>
<td>$55.00</td>
<td>$78.0K</td>
<td>330</td>
<td align="right">155</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Novo Nordisk</h3>
<ul>
<li>With a trading volume of 8,386,138, the price of NVO is up by 1.78%, reaching $59.37.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 15 days from now.</li>
</ul>
<h3>What The Experts Say On Novo Nordisk</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $64.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has revised its rating downward to Market Perform, adjusting the price target to $64. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Novo Nordisk's Options Frenzy: What You Need to Know

<a href="https://www.biopharmadive.com/news/novo-oral-semaglutide-fda-approval-application-obesity/745882/">https://www.biopharmadive.com/news/novo-oral-semaglutide-fda-approval-application-obesity/745882/</a>

Novo Announces It Has Submitted Its Obesity Pill For FDA Approval

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$450.00</td>
<td>$52.0K</td>
<td>100</td>
<td>4.3K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$33.3K</td>
<td>3.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$105.00</td>
<td>$134.3K</td>
<td>992</td>
<td>550</td>
</tr>
<tr>
<td>BHVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$17.50</td>
<td>$26.6K</td>
<td>20</td>
<td>401</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$780.00</td>
<td>$25.9K</td>
<td>1.0K</td>
<td>384</td>
</tr>
<tr>
<td>SLNO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$25.0K</td>
<td>4.4K</td>
<td>262</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>897</td>
<td>233</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$70.00</td>
<td>$61.9K</td>
<td>336</td>
<td>39</td>
</tr>
<tr>
<td>MTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1180.00</td>
<td>$58.8K</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$75.00</td>
<td>$29.0K</td>
<td>10</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 100 contract(s) at a $450.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $52.0K, with a price of $520.0 per contract. There were 100 open contracts at this strike prior to today, and today 4332 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option sweep that happens to be bullish, expiring in 273 day(s) on January 16, 2026. This event was a transfer of 34 contract(s) at a $50.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $33.3K, with a price of $980.0 per contract. There were 3960 open contracts at this strike prior to today, and today 1145 contract(s) were bought and sold. 
• For BNTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), we notice a call option sweep that happens to be bearish, expiring in 28 day(s) on May 16, 2025. This event was a transfer of 363 contract(s) at a $105.00 strike. This particular call needed to be split into 52 different trades to become filled. The total cost received by the writing party (or parties) was $134.3K, with a price of $370.0 per contract. There were 992 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• Regarding BHVN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>), we observe a put option trade with bearish sentiment. It expires in 28 day(s) on May 16, 2025. Parties traded 140 contract(s) at a $17.50 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $190.0 per contract. There were 20 open contracts at this strike prior to today, and today 401 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be bullish, expiring in 1 day(s) on April 17, 2025. This event was a transfer of 4 contract(s) at a $780.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.9K, with a price of $6480.0 per contract. There were 1032 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• Regarding SLNO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>), we observe a call option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 50 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 4483 open contracts at this strike prior to today, and today 262 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 637 day(s) on January 15, 2027. Parties traded 25 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $1050.0 per contract. There were 897 open contracts at this strike prior to today, and today 233 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a put option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 38 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $61.9K, with a price of $1630.0 per contract. There were 336 open contracts at this strike prior to today, and today 39 contract(s) were bought and sold. 
• Regarding MTD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), we observe a call option trade with bearish sentiment. It expires in 182 day(s) on October 17, 2025. Parties traded 12 contract(s) at a $1180.00 strike. The total cost received by the writing party (or parties) was $58.8K, with a price of $4900.0 per contract. There were 0 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we notice a call option trade that happens to be neutral, expiring in 336 day(s) on March 20, 2026. This event was a transfer of 5 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $5814.0 per contract. There were 10 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BHVN

BNTX

SLNO

SRPT

10 Health Care Stocks Whale Activity In Today's Session

Three <a href="https://www.benzinga.com/etfs">healthcare-themed ETFs</a> were in sharp spotlight Thursday as the sector got through a wild trading day, fueled by UnitedHealth&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) earnings disappointment and steep stock decline. While insurers weighed down on broad healthcare gauges, a drugmakers rally, led by Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), limited the damage.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a>
ETFs In Spotlight
Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)
<ol>
<li></li>
</ol>
1-Day Return (Thursday): -0.6%
Top holdings of this fund are Eli Lilly, UnitedHealth, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>). UnitedHealth dropped 2.4%, spooking XLV early in the session. The ETF trimmed losses, however, as Eli Lilly rallied 14.3% on <a href="https://www.benzinga.com/general/biotech/25/04/44878381/eli-lilly-rallies-over-14-notches-best-day-since-june-2000-on-oral-weight-loss-drug-results-analysts-react">good weight-loss pill trial news</a>, calling out the group&#8217;s internal divergency. Barring Thursday&#8217;s turmoil, though, XLV is off just 1.5% for the year so far and commands a 17x forward-earnings multiple—below its five-year history and the large-cap S&amp;P 500&#8217;s 20x multiple, according to Barron&#8217;s.
iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)
<ol start="2">
<li></li>
</ol>
1-Day Performance: +4.6%
IHE surged as investors rotated into large-cap pharma stocks, bolstered by Eli Lilly's rally. The gains came despite a nearly 8% drop in Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Lilly's rival in the GLP-1 space.
SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)
<ol start="3">
<li></li>
</ol>
1-Day Performance: +2.15%
XPH tracked gains across a broader basket of pharmaceutical names, benefiting from bullish sentiment on drugmakers following Lilly's breakthrough.
Market Context: A Sector Of Contrasts
UnitedHealth&#8217;s <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">poor earnings and soft guidance</a> spooked healthcare investors, highlighting how exposed insurers are to firm-specific disappointments and policy-level risks. The 22% decline in the stock not only heavily burdened XLV—where it is the second-largest position—but pulled down peers CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) too.
However, the overall message of the day was one of subtlety and not panic. Eli Lilly&#8217;s explosion proved the influence of innovation in developing market-driving catalysts within the health-care sector. It provided the stimulus that helped neutralize weakness within managed care and indicated how investors in ETFs are able to still uncover segments of strength despite sector-wide selloffs.
At the same time, Johnson &amp; Johnson kept its steady pace going with the help of strong earnings.
Device and medical equipment manufacturers like Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), Zimmer Biomet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), and Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) are also attracting investor attention as Wall Street is wagering on secular demand from the aging population.
Takeaway
The health care industry remains far from monolithic. Thursday&#8217;s ETF action underscored the increasing divide between pressured insurers and pharma names benefiting from innovation tailwinds. For investors in ETFs, the message is simple: thematic selectivity is key. Though political headlines and earnings fluctuations might continue to shock portions of the industry, solid fundamentals within pharma and medtech imply there&#8217;s still ample healthy opportunity to go around.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44876466/the-10k-handbag-hoax-tiktoks-trade-war-puts-luxury-etfs-in-the-hot-seat">The $10K Handbag Hoax? TikTok&#8217;s Trade War Puts Luxury ETFs In The Hot Seat</a></li>
</ul>
Image: Shutterstock/The Image Party

Sector ETFs

ETFs

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot

Wall Street experienced a <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44873779/wall-street-rebounds-eli-lilly-rallies-unitedhealth-group-plummets-whats-driving-markets-thursday">resurgence in risk appetite</a> on Thursday as optimism grew around trade negotiations. President Donald Trump expressed confidence in reaching agreements with both the European Union and China. 
On Thursday, the Dow Jones Industrial Average fell 1.3% to close at 39,142.23. The Nasdaq dipped 0.13%, finishing at 16,286.45. Meanwhile, the S&amp;P 500 edged up 0.13%, ending the day at 5,282.70.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Netflix Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)
Netflix shares rose by 1.19% to close at $973.03, reaching an intraday high of $984.70 and a low of $956. The stock&#8217;s 52-week range is $542.01 to $1064.50. In the after-hours trading, shares spiked 3.5% to $1,006.79. The streaming giant reported its first-quarter financial results, emphasizing efforts to <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">improve and expand</a> its offerings. The company continues to focus on enhancing its content library and user experience. For the period, revenue came in at $10.54 billion, a spike of 12.5% on a year-over-year basis. Earnings per share were reported at $6.61, beating the estimate of $5.74.
UnitedHealth Group Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)
UnitedHealth&#8217;s stock plummeted by 22.38% to $454.11, with a daily high of $489.79 and a low of $447.10. The 52-week range stands at $438.50 to $630.73. The healthcare giant faced a steep decline after reporting disappointing quarterly results, attributed to rising healthcare costs. CEO Andrew Witty stated that the current cost structure is <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">unsustainable</a>, leading to a downward revision of earnings guidance. UnitedHealth cut fiscal 2025 earnings guidance and expects it to come in the range of $26 to $26.50 from the earlier range of $29.50 to $30 per share.
See Also:&nbsp;<a href="https://benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions" target="_blank" rel="noreferrer noopener">Mark Cuban Says This Trump Healthcare Order &#8216;Could Save Hundreds Of Billions&#8217;</a>
Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)
Novo Nordisk shares fell by 7.63% to $58.08, with an intraday high of $59.06 and a low of $57.28. The stock&#8217;s 52-week range is $57.28 to $148.15. An analyst from BMO Capital Markets downgraded the stock, citing concerns about its performance in the&nbsp;<a href="https://www.benzinga.com/25/04/44876055/novo-nordisk-may-lag-behind-eli-lilly-in-cardiometabolic-race-analyst-downgrades-stock">cardiometabolic space</a>&nbsp;compared to competitors like Eli Lilly.
Trump Media &amp; Technology Group Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
Trump Media&#8217;s stock surged by 11.65% to $22.04, hitting a high of $22.77 and a low of $19.82. The 52-week range is $11.75 to $56.55. The company saw its shares rise after filing a complaint with the SEC regarding potential&nbsp;<a href="https://www.benzinga.com/25/04/44871004/whats-going-on-with-trump-media-technology-stock-today">market manipulation</a>&nbsp;and unusual trading patterns.
Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla&#8217;s stock edged down by 0.07% to close at $241.38, with a high of $244.34 and a low of $237.68. The 52-week range is $138.80 to $488.54. Despite a decline in new vehicle registrations in California, Tesla remains a significant player in the <a href="https://www.benzinga.com/tech/25/04/44857987/tesla-experiences-151-decline-in-new-vehicle-registrations-in-california-report">electric vehicle market</a>, according to recent data.
Trump Media or Netflix? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Find out</a> how they stack up in terms of Momentum and Growth with Benzinga Edge Stock Rankings. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="787" height="106" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17215703/Screenshot-2025-04-18-at-10.56.23.png" alt="" class="wp-image-877876" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17215703/Screenshot-2025-04-18-at-10.56.23.png 787w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17215703/Screenshot-2025-04-18-at-10.56.23-300x40.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17215703/Screenshot-2025-04-18-at-10.56.23-768x103.png 768w" sizes="(max-width: 787px) 100vw, 787px" /></a></figure>
Photo Sutthiphong Chandaeng via Shutterstock
Prepare for the day&#8217;s trading <a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a> by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44880757/cathie-woods-pours-another-4-95-million-into-solana-staking-etf-dumps-bitcoin-etf-again">Cathie Wood&#8217;s Pours Another $4.95 Million Into Solana Staking ETF, Dumps Bitcoin ETF Again</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today

Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple <a href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential">in size by 2030. </a>
The stock surged, closing the day up 14.36% to $839.96, marking its best performance since June 2000.
In a Thursday note, Goldman Sachs analyst Asad Haider, CFA said Eli Lilly's first Phase 3 trial of orforglipron — a once-daily oral treatment for type 2 diabetes and obesity — hit its top-line targets with best-case scenario results across weight loss, blood sugar control and safety.
<h1 class="wp-block-heading">The Data That Moved the Market</h1>
Lilly's ACHIEVE-1 trial evaluated orforglipron, an oral GLP-1 (glucagon-like peptide-1) receptor agonist, in adults with type 2 diabetes. 
At the highest 36mg dose, patients saw an average weight reduction of 7.9% over 40 weeks — translating to 16 pounds of weight loss, substantially above the placebo-adjusted rate of 6.3%.
For context, that outperforms Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) 's Rybelsus — currently the only oral GLP-1 treatment available — which achieved a 4.9% weight loss at its peak dosage in the SUSTAIN-1 trial.
In addition, orforglipron delivered A1C reductions of up to 1.6%, aligning with injectable semaglutide's performance and hitting a critical target in glycemic control. 
More than 65% of participants on the highest dose achieved an A1C level at or below 6.5%, a threshold defined by the American Diabetes Association as the benchmark for controlled diabetes.
Discontinuation due to side effects was 8% at the top dose, and there were no reported liver injury signals — two key safety indicators watched closely by investors after setbacks in rival studies.
<h1 class="wp-block-heading">Why Wall Street Is Cheering</h1>
Goldman Sachs analysts wrote that the trial marks "an important clearing event for LLY shares," especially after recent disappointments from rivals like Novo Nordisk A/S and Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) in their respective obesity pipelines. 
The investment bank reiterated a Buy rating and $888 price target on the stock, citing Lilly's potential to dominate a market expected to balloon from $28 billion today to $95 billion by 2030.
Their internal forecasts see risk-adjusted peak sales for orforglipron hitting $23.5 billion by 2035, with commercial rollout starting globally in 2026. That's well above the Street's consensus of $16.8 billion.
"This data trends toward our bull case scenario," Goldman said, noting that investor caution ahead of the binary trial event was likely keeping shares from rallying sooner.
<h1 class="wp-block-heading">Is Orforglipron The ‘Ozempic In A Pill'?</h1>
Tim Anderson, equity analyst at Bank of America, said Thursday's results were "pretty much a best-case scenario," covering all four key investor watchpoints: weight loss, blood sugar control, tolerability and safety.
Calling orforglipron a potential "Ozempic in a pill," Anderson highlighted its small molecule structure as a key differentiator. 
Unlike Novo's Rybelsus, which is a peptide with cold-chain storage limitations, orforglipron's easier manufacturing and oral delivery method could unlock demand in emerging markets, where injectables face logistical hurdles.
"Positive results like these, in a skittish market, should be received well," Anderson said, adding that the company remains one of the two dominant incumbents in the diabetes and obesity drug space.
Bank of America reiterated its Buy rating and $1,000 price objective, citing Eli Lilly's superior growth metrics: while the stock trades at roughly three times the average pharma price-to-earnings multiple, its expected earnings-per-share growth is five to six times higher than peers, making it relatively attractive on a PEG basis.
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44873779/wall-street-rebounds-eli-lilly-rallies-unitedhealth-group-plummets-whats-driving-markets-thursday">Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What&#8217;s Driving Markets Thursday?</a></li>
</ul>

Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React

BMO Capital Markets analyst Evan David Seigerman downgraded Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) from Outperform to Market Perform,<a target="_blank" href="https://www.benzinga.com/quote/NVO/analyst-ratings" rel="noreferrer noopener"> lowering the price forecast from $105 to $64.</a>
Per Seigerman, Novo Nordisk&#8217;s stock may underperform compared to peers in the cardiometabolic space, particularly Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">Lilly&#8217;s Diabetes Pill Clears Major Trial, Analyst Points To Global Potential</a>
The analyst highlights that Lilly&#8217;s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo Nordisk&#8217;s Ozempic and Wegovy.
Seigerman noted that although Novo Nordisk initially benefited from being first to market with semaglutide, that early lead is quickly diminishing.
Eli Lilly&#8217;s tirzepatide is rapidly capturing market share, and the analyst projects this momentum to continue.
The analyst pointed out that recent clinical comparisons have shown tirzepatide outperforming semaglutide, and this advantage is already reflected in U.S. script data.
According to Seigerman, tirzepatide&#8217;s continued growth to further slow the momentum of Novo Nordisk&#8217;s Wegovy and Ozempic.
In the near term, the analyst is doubtful that Novo Nordisk&#8217;s upcoming drug CagriSema will be able to effectively compete, citing disappointing results from the REDEFINE trial.
With additional drugs like orforglipron and retatrutide in Lilly&#8217;s pipeline, the competitive pressure on Novo Nordisk is likely to intensify going forward.
Additionally, upcoming data on orforglipron could introduce more competition and weigh on Novo Nordisk&#8217;s stock.
Overall, the analyst does not expect the company&#8217;s 2025 developments to be strong enough to reverse this trend or significantly boost its market position.
Price Action: Novo Nordisk shares are trading lower by 7.1% to $58.41 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44866751/forge-global-eyes-strategic-expansion-with-10m-accuidity-acquisition" target="_blank" rel="noreferrer noopener">Forge Global Eyes Strategic Expansion With $10 Million Accuidity Acquisition</a></li>
</ul>
Image: Shutterstock

Movers

Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock

Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Thursday reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diet and exercise alone</a>.
In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, <a target="_blank" href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" rel="noreferrer noopener">using the efficacy estimand</a>.
BofA Securities analyst Tim Anderson writes, &#8220;Arguably one of the biggest, most important, most closely-watched pipeline events in large cap biopharma has just played out. And it was favorable.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Anderson says the only other current oral GLP-1 drug is Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Rybelsus (semaglutide), a peptide with some limitations.
&#8220;The &#8220;key&#8221; with orforglipron is that it is a &#8220;small molecule&#8221; drug, meaning easy to scale and produce &#8211; recall past manufacturing problems with injectable GLP-1s (from Eli Lilly and Novo Nordisk),&#8221; Anderson adds.
An oral drug like this can help expand obesity treatment outside the U.S., especially in developing countries where keeping medications cold is difficult.
BofA writes Eli Lilly is mainly focusing on selling the oral version in markets outside the U.S., where prices need to be lower. Since oral drugs are easier and cheaper to produce, this makes sense.
&#8220;Positive results like these, in a skittish market, should be received well,&#8221; BofA writes.
BofA forecasts 2030 orforglipron sales of around $10 billion compared to a consensus of around $9 billion.
The analyst maintains the Buy rating, with a price forecast of $1,000.
Anderson writes, &#8220;On a macro perspective, we believe that given the strength of the Phase II data, positive Phase III ACHIEVE-1 efficacy results were expected. However, in light of Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) recent discontinuation of danuglipron, tolerability and hepatotoxicity have emerged as more important clinical attributes, in our view.&#8221;
Price Action: LLY stock is up 16.3% at $854.84 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44866751/forge-global-eyes-strategic-expansion-with-10m-accuidity-acquisition" target="_blank" rel="noreferrer noopener">Forge Global Eyes Strategic Expansion With $10 Million Accuidity Acquisition</a></li>
</ul>
Photo by shisu_ka via Shutterstock

Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential

Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump&#8216;s 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs) in the U.S. healthcare system.
What Happened: In a post on X, addressed to President Trump on Wednesday, Cuban cheered the order that aims to reform PBMs, entities that control 80% of U.S. prescriptions. He emphasized the potential of the order to save billions and improve patient wellness.
Cuban&#8217;s proposals include separating&nbsp;formularies from PBMs to focus&nbsp;on wellness, mandating transparency in&nbsp;claims data to improve patient&nbsp;outcomes, and eliminating&nbsp;specialty drug tiers that inflate&nbsp;costs. He also urged action on issues such as the 340B program's double-dipping, which a 2023 study estimated to cost hospitals $500 million each year.
&#8220;Make them about wellness, not pay for play like a grocery store endcap. This ends rebates and allows for net pricing. It also allows for better care and wellness,&#8221; stated the Shark Tank celebrity. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Gotta be honest. The <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> EO on healthcare and in particular, drug pricing could save hundreds of billions. Here is how: 1. Divorce formularies from PBMs. Require them to come from independent organizations with no economic incentive from the formulary Make them…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1912628036668739778?ref_src=twsrc%5Etfw">April 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban, the founder of Cost Plus Drug Company, also criticized&nbsp;PBM tactics like biosimilar substitution&nbsp;calls, where they push doctors&nbsp;to prescribe pricier drugs for&nbsp;higher margins, a practice enabled&nbsp;by vertical integration. He referenced the&nbsp;1990s FTC concerns when pharmaceutical&nbsp;companies acquired PBMs, leading to&nbsp;mandated open formularies.
SEE ALSO: <a href="https://benzinga.com/news/global/25/04/44856008/china-dismisses-trumps-tariff-numbers-game-files-wto-complaint-talks-can-only-proceed-based-on-mutual" target="_blank" rel="noreferrer noopener">China Dismisses Trump&#8217;s Tariff &#8216;Numbers Game,&#8217; Files WTO Complaint: Talks Can Only Proceed Based On &#8216;Mutual Respect&#8217;</a>
Why It Matters: Trump&#8217;s executive order comes as part of a <a href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">broader effort</a> to lower drug prices and reduce Medicare costs. The administration is set to negotiate prices for a second batch of 15 medications, including Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, along with Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) cancer treatments Ibrance and Xtandi
Additionally, the Trump administration has disclosed plans for a "major tariff" on <a href="https://www.benzinga.com/government/regulations/25/04/44847222/trump-administration-opens-probe-into-foreign-drug-imports-eyes-tariffs-under-national-security-law">foreign pharmaceuticals</a>. This move could potentially impact the pharmaceutical industry, with the U.S. Department of Commerce launching an investigation into the potential national security risks posed by the country's reliance on imported pharmaceuticals and key drug ingredients.
Meanwhile, Cuban, an outspoken critic of the Trump administration, has always pushed for affordable and universal healthcare. He has consistently pointed out the shortcomings of the <a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">U.S. healthcare system</a>, which is further complicated by large insurance companies and pharmacy benefit managers.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/44858847/nancy-pelosi-called-us-china-trade-a-job-loserold-remarks-reemerge-amid-trump-tariff-push" target="_blank" rel="noreferrer noopener">Nancy Pelosi Called US-China Trade &#8220;A Job Loser:&#8221; Old Remarks Reemerge Amid Trump Tariff Push</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mark Cuban Says This Trump Healthcare Order 'Could Save Hundreds Of Billions'

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Longbow Research analyst David Macgregor initiated coverage on Twin Disc, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWIN#NASDAQ">TWIN</a>) with a Buy rating and announced a price target of $12. Twin Disc shares closed at $6.66 on Wednesday. <a href="https://www.benzinga.com/quote/TWIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Blair Abernethy initiated coverage on RedCloud Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCT#NASDAQ">RCT</a>) with a Buy rating and announced a price target of $5. RedCloud shares closed at $1.71 on Wednesday. <a href="https://www.benzinga.com/quote/RCT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Eva Fortea Verdejo initiated coverage on Bicara Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) with an Underweight rating and announced a price target of&nbsp;$8. Bicara Therapeutics shares closed at $11.76 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo initiated coverage on Relay Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with an Equal-Weight rating and announced a price target of&nbsp;$4. Relay Therapeutics shares closed at $2.61 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Sam Eiber initiated coverage on Evolus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) with a Buy rating and announced a price target of $21. Evolus shares closed at $10.11 on Wednesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TWIN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-1024x593.png" alt="" class="wp-image-876433" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44857276/netflix-unitedhealth-group-and-3-stocks-to-watch-heading-into-thursday">Netflix, UnitedHealth Group And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

AMKR

BCAX

EOLS

RLAY

TWIN

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup cut Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) price target from $162 to $138. Citigroup analyst Vikram Bagri upgraded the stock from Neutral to Buy. Generac shares closed at $110.65 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/GNRC/analyst-ratings">view this stock</a>.</li>
<li>Chardan Capital slashed the price target for Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) from $40 to $33. Chardan Capital analyst Daniil Gataulin maintained a Buy rating. Adverum Biotechnologies shares closed at $2.98 on Wednesday. See how other analysts<a href="https://www.benzinga.com/quote/ADVM/analyst-ratings"> view this stock</a>.</li>
<li>Rosenblatt cut Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) price target from $305 to $290. Rosenblatt analyst Chris Brendler maintained a Buy rating. Coinbase shares closed at $172.21 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">view this stock</a>.</li>
<li>Evercore ISI Group slashed the price target for Prologis, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) from $111 to $106. Evercore ISI Group analyst Steve Sakwa maintained an In-Line rating. Prologis shares closed at $100.29 on Wednesday. <a href="https://www.benzinga.com/quote/PLD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $289 to $297. B of A Securities analyst Joshua Shanker maintained a Neutral rating. Progressive shares closed at $275.13 on Wednesday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital slashed Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) price target from $105 to $64. BMO Capital analyst Evan David Seigerman downgraded the stock from Outperform to Market Perform. Novo Nordisk shares settled at $62.88 on Wednesday. <a href="https://www.benzinga.com/quote/NVO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co increased Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) price target from $29 to $32. HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating. Oculis Holding shares closed at $18.02 on Wednesday. <a href="https://www.benzinga.com/quote/OCS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Scotiabank raised Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) price target from $600 to $700. Scotiabank analyst Allan Verkhovski upgraded the stock from Sector Perform to Sector Outperform. Intuit shares closed at $588.08 on Wednesday.  <a href="https://www.benzinga.com/quote/INTU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised the price target for ServiceTitan, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) from $120 to $130. Canaccord Genuity analyst David Hynes maintained a Buy rating. ServiceTitan shares settled at $117.66 on Wednesday. <a href="https://www.benzinga.com/quote/TTAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods slashed Walker &amp; Dunlop, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) price target from $105 to $95. Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained an Outperform rating. Walker &amp; Dunlop shares closed at $73.65 on Wednesday. <a href="https://www.benzinga.com/quote/WD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying INTU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="604" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-1024x604.png" alt="" class="wp-image-876630" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-1024x604.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-768x453.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21.png 1088w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44857276/netflix-unitedhealth-group-and-3-stocks-to-watch-heading-into-thursday">Netflix, UnitedHealth Group And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Price Target

ADVM

COIN

GNRC

INTU

TTAN

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

WIIM

Novo Nordisk shares are trading lower after BMO Capital downgraded the stock from Outperform to Market Perform and cut its price target from $105 to $64.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keybanc analyst Jackson Ader downgraded the rating for Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from Overweight to Sector Weight. Microsoft shares closed at $371.61 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Laidlaw &amp; Co. analyst Yale Jen downgraded iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) from Buy to Hold. iCAD shares closed at $3.07 on Wednesday. <a href="https://www.benzinga.com/quote/ICAD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Steve Barger downgraded Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) from Overweight to Sector Weight. Amkor Tech shares closed at $16.15 on Wednesday. <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Evan David Seigerman downgraded Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) from Outperform to Market Perform and lowered the price target from $105 to $64. Novo Nordisk shares closed at $62.88 on Wednesday. <a href="https://www.benzinga.com/quote/NVO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Steve Barger downgraded the rating for Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) from Overweight to Sector Weight. Teradyne shares closed at $71.16 on Wednesday.  <a href="https://www.benzinga.com/quote/TER/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MSFT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17073357/image-1-8-1024x622.png" alt="" class="wp-image-876378" style="width:520px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17073357/image-1-8-1024x622.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17073357/image-1-8-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17073357/image-1-8-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17073357/image-1-8.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44857276/netflix-unitedhealth-group-and-3-stocks-to-watch-heading-into-thursday">Netflix, UnitedHealth Group And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

ICAD

MSFT

This Microsoft Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

BMO Capital analyst Evan David Seigerman downgrades Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) from Outperform to Market Perform and lowers the price target from $105 to $64.

BMO Capital Downgrades Novo Nordisk to Market Perform, Lowers Price Target to $64

Press Releases

NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

NVO FINAL DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action – NVO

NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline

Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

NVO DEADLINE ALERT: Novo Nordisk (NVO) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 25th Deadline in Securities Class Action

Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights – NVO

Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

BMO Capital

Cantor Fitzgerald

Argus Research

Morgan Stanley

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Comments

Novo Nordisk

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
10:17 AMFeb 19, 2025	CALL	$110.00	Jan 16, 2026	262	1200	1200	62	1937	TRADE	BEARISH
11:16 AMFeb 18, 2025	CALL	$80.00	May 16, 2025	17	202	1000	53	378	SWEEP	BULLISH
09:47 AMFeb 18, 2025	CALL	$50.00	Apr 17, 2025	-12	0	200	0	2	TRADE	BULLISH